0.5498
price up icon19.00%   0.0878
pre-market  Pre-market:  .55   0.0002   +0.04%
loading
Psyence Biomedical Ltd stock is traded at $0.5498, with a volume of 181.30K. It is up +19.00% in the last 24 hours and down -9.17% over the past month. Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$0.462
Open:
$0.4866
24h Volume:
181.30K
Relative Volume:
0.63
Market Cap:
$1.83M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+25.50%
1M Performance:
-9.17%
6M Performance:
-92.43%
1Y Performance:
-99.13%
1-Day Range:
Value
$0.4849
$0.5499
1-Week Range:
Value
$0.38
$0.5499
52-Week Range:
Value
$0.3666
$108.00

Psyence Biomedical Ltd Stock (PBM) Company Profile

Name
Name
Psyence Biomedical Ltd
Name
Phone
-
Name
Address
-
Name
Employee
10
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
PBM's Discussions on Twitter

Compare PBM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PBM
Psyence Biomedical Ltd
0.5498 1.83M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Psyence Biomedical Ltd Stock (PBM) Latest News

pulisher
Apr 23, 2025

Psyence Biomedical Faces Nasdaq Delisting Amid Shareholder Approval for Reverse Stock Split - TipRanks

Apr 23, 2025
pulisher
Apr 20, 2025

Psyence BioMed gets Nasdaq notice for non-compliance - MSN

Apr 20, 2025
pulisher
Apr 18, 2025

Psyence Group consolidates its shares - Crain's Chicago Business

Apr 18, 2025
pulisher
Apr 17, 2025

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - TradingView

Apr 17, 2025
pulisher
Apr 16, 2025

Psyence BioMed invests half a million into natural psychedelics operator PsyLabs - Mugglehead Magazine

Apr 16, 2025
pulisher
Apr 15, 2025

Psyence BioMed boosts stake in PsyLabs with $500k investment By Investing.com - Investing.com Nigeria

Apr 15, 2025
pulisher
Apr 15, 2025

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement - Newsfile

Apr 15, 2025
pulisher
Apr 11, 2025

Psyence Biomedical Transitions CRO for Psilocybin Trial in April 2025 - TipRanks

Apr 11, 2025
pulisher
Apr 08, 2025

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia - Newsfile

Apr 08, 2025
pulisher
Apr 08, 2025

Major Expansion: Psyence's Breakthrough Cancer Mental Health Trial Targets Untreated Disorder - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

Psyence Biomedical reports corporate update By Investing.com - Investing.com Australia

Apr 02, 2025
pulisher
Apr 01, 2025

Psyence Biomedical reports corporate update - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Psyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical Trials - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Psyence Biomedical Announces Special Shareholder Meeting for Share Consolidation - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Psyence's Game-Changing Phase IIb Trial Takes On Cancer Mental Health Crisis - Stock Titan

Mar 31, 2025
pulisher
Mar 25, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. Stein - The Manila Times

Mar 25, 2025
pulisher
Mar 21, 2025

Psyence Biomedical Ltd. (NASDAQ:PBMWW) Short Interest Down 13.1% in February - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Psyence Biomed expands advisory board with psychopharmacology expert By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Psyence Biomed expands advisory board with psychopharmacology expert - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein - Newsfile

Mar 18, 2025
pulisher
Mar 18, 2025

Top Columbia Psychiatrist Joins Psyence's Psilocybin Clinical Trial Team - StockTitan

Mar 18, 2025
pulisher
Mar 10, 2025

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - The Manila Times

Mar 10, 2025
pulisher
Mar 06, 2025

Psyence Biomedical files to sell 13.81M common shares for holders - MSN

Mar 06, 2025
pulisher
Mar 04, 2025

Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN -March 04, 2025 at 04:48 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Psyence Biomedical Ltd Files For Mixed Shelf Of Up To $75LN - TradingView

Mar 04, 2025
pulisher
Feb 26, 2025

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can This Johns Hopkins Psychedelics Expert Accelerate Psyence's Psilocybin Breakthroughs? - StockTitan

Feb 26, 2025
pulisher
Feb 07, 2025

Psyence Biomedical Ltd (PBM) Stock: A Value Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 06, 2025

Ratio Analysis: Unpacking Psyence Biomedical Ltd (PBM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Feb 06, 2025
pulisher
Jan 23, 2025

Psyence Biomedical Adjusts Financials for Reverse Stock Split - TipRanks

Jan 23, 2025
pulisher
Jan 16, 2025

Short Interest in Psyence Biomedical Ltd. (NASDAQ:PBMWW) Decreases By 41.0% - Defense World

Jan 16, 2025
pulisher
Jan 05, 2025

Psyence enters into $25M common stock purchase agreement with White Lion Capital - MSN

Jan 05, 2025
pulisher
Dec 31, 2024

Psyence Biomedical Issues Pre-Funded Share Purchase Warrant - TipRanks

Dec 31, 2024
pulisher
Dec 28, 2024

Psyence Biomed Announces Closing of $2.0 Million Private Placement - The Manila Times

Dec 28, 2024
pulisher
Dec 27, 2024

Psyence Biomed (PBM) Raises $2M in Private Placement with Warrant Coverage, Led by H.C. Wainwright - StockTitan

Dec 27, 2024
pulisher
Dec 24, 2024

Psyence Biomedical Regains Nasdaq Compliance, Fortifying Market Position - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

Psyence Biomed announces $2 million private placement By Investing.com - Investing.com Nigeria

Dec 24, 2024

Psyence Biomedical Ltd Stock (PBM) Financials Data

There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):